Vor Biopharma

Robert Ang, President and CEO

Oct. 12 | 5:15pm | UBC Ballroom  

Cambridge, MA 

(NASDAQ: VOR) 

In-person Presentation 

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. 

www.vorbio.com 



By using this website you agree to accept our Privacy Policy and Terms & Conditions